Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary CryptoMapTM platform.
All the latest company news, press releases and updates from Epitopea.

Drug Discovery World

November 10, 2026

First patient receives mRNA immunotherapy for ovarian cancer

The first patient has been successfully dosed in OVACT, Epitopea’s first-in-human Phase I/Ib clinical trial evaluating its lead programme, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer (HGSOC).

OVACT is designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in HRP+/BRCA-wildtype advanced HGSOC patients.

Up to 30 women will be enrolled into the trial across up to 10 leading clinical centres in the UK.

HGSOC remains one of the most difficult-to-treat solid tumours, with around 80% of patients presenting with advanced or metastatic disease.

While most women respond to first-line platinum chemotherapy, nearly all ultimately relapse and progress to platinum-resistant disease.

Existing maintenance options are only effective in half of the ovarian cancer population and leave a major therapeutic gap among HRP+/BRCA-wildtype patients.

Professor Susana Banerjee, the Chief Investigator of Epitopea’s OVACT trial, Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust and Professor in Women’s Cancers at The Institute of Cancer Research, London, said: “It is exciting to offer patients the option of the OVACT trial and I am delighted that we are underway with the first patient treated. The CryptiVax-1001 vaccine has the potential to meaningfully extend remission for women where currently available maintenance therapies deliver limited durable benefit.”

CryptiVax-1001 is an mRNA immunotherapy designed to drive targeted immune responses using a set of tumour-specific antigens chosen for their immunogenicity and broad patient coverage.

Dr Klaus Edvardsen, Chief Medical Officer of Epitopea, commented: “HGSOC is the most common and aggressive subtype of ovarian cancer. Treating the first patient with CryptiVax-1001 in our OVACT Phase I/Ib trial for HGSOC is a major milestone for Epitopea. Epitopea’s approach targets a novel repertoire of tumour-specific antigens that have been selected to provide broader patient benefit.”

See original publication for the full article
Source: Drug Discovery World

Related News

Revealing Novel Targets For Next Generation Immunotherapies
© 2022 – 2026 Epitopea Ltd | All Rights Reserved
Created by FDM Digital
arrow-down